Evidence map›Paper›PMID 42582316›Full record

ArticleFrontiers in neuroscience2026

Grip strength as a translational biomarker for peripheral nerve injury and recovery.

Christoph A Schroen

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Christoph A SchroenLeni & Peter W. May Department of Orthopedic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A central challenge in peripheral nerve injury care is determining whether an in-continuity injury will recover spontaneously or require early surgical intervention. This determination currently depends on serial observation, during which the window for effective intervention may narrow. This Perspective discusses grip strength as a translational biomarker for peripheral nerve injury and recovery, with emphasis on rodent forelimb nerve injury models. In both rats and human patients, grip strength can be used to assess whether a motor nerve can activate its target muscle sufficiently to generate force. This shared functional endpoint gives grip strength particular translational value and distinguishes it from many preclinical functional assays used only in animal research. In rodent models of in-continuity nerve stretch injury, structurally distinct injury grades have produced markedly different grip strength recovery profiles over time, linking structural injury severity to long-term functional outcomes. Grip strength has also served as a primary functional endpoint for evaluating intraoperative electrical stimulation as an early prognostic tool and for measuring treatment effects after nerve injury. The grasping test offers a practical, reliable and low-cost method for quantifying forelimb motor recovery, but broader adoption will require standardization of testing protocols and reporting. Grip strength should not be interpreted in isolation, as it reflects the combined function of nerve signaling and target muscle force generation. Instead, it is most informative when combined with histological, electrophysiological, sensory, imaging, and clinical assessments. Standardized use of grip strength may therefore improve the translational relevance of preclinical nerve injury research.

Indexed as

grasping testgrip strengthnerve injuryneuroclasisrodent studytranslational

Identifiers

PMID42582316
PMCPMC13457387

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.